cellular
uptak
therapeut
oligonucleotid
subsequ
intracellular
traffick
target
site
repres
major
technic
hurdl
biolog
effect
potenti
drug
accordingli
laboratori
worldwid
focu
develop
suitabl
deliveri
system
among
differ
avail
nonvir
system
like
cation
polym
cation
liposom
polymer
nanoparticl
cellpenetr
peptid
cpp
repres
attract
concept
bypass
problem
poor
membran
permeabl
charg
macromolecul
uptak
per
se
case
repres
main
obstacl
nucleic
acid
deliveri
vitro
becom
increasingli
appar
intracellular
traffick
bottleneck
consequ
order
optim
given
deliveri
system
sidebysid
analysi
nucleic
acid
cargo
intern
correspond
biolog
effect
requir
determin
overal
efficaci
review
concentr
peptidemedi
deliveri
sirna
steric
block
oligonucleotid
discuss
differ
method
quantit
assess
amount
cargo
taken
correl
number
biolog
effect
appli
easi
handl
report
system
illustr
current
limit
nonvir
nucleic
acid
deliveri
system
present
data
exampl
discuss
option
enhanc
traffick
molecul
entrap
cellular
compart
oligonucleotidebas
strategi
use
modul
vast
varieti
cellular
function
repres
promis
altern
convent
therapi
review
see
among
differ
oligonucleotid
therapeut
potenti
aptam
transcript
factorbind
decoy
oligonucleotid
ribozym
triplexform
oligonucleotid
tfo
immunostimulatori
cpg
motif
antisens
oligonucleotid
small
interf
rna
sirna
antagomir
nowaday
potenti
macromolecular
drug
gener
either
rel
easili
deriv
ration
design
eg
antisens
sirna
straightforward
select
process
eg
aptam
one
main
advantag
proteinor
peptidebas
approach
compris
high
specif
target
nonimmunogen
howev
despit
advanc
major
impedi
develop
nucleic
acidbas
strategi
treatment
prevent
diseas
rel
ineffici
mean
effect
deliv
macromolecul
desir
target
cell
although
viral
vector
wide
use
transfer
genet
materi
cell
bear
inher
risk
patient
encount
sever
immunolog
respons
even
develop
cancer
result
problem
much
attent
paid
recent
year
develop
nonvir
deliveri
system
concept
address
correspond
author
institut
molekular
medizin
zu
ratzeburg
alle
germani
tel
fax
email
restl
immuniluebeckd
includ
assort
fairli
unrel
approach
yield
variou
degre
enhanc
cellular
uptak
nucleic
acid
current
liposom
cation
polym
use
standard
tool
transfect
cell
vitro
howev
procedur
character
signific
lack
effici
accompani
high
level
toxic
render
mostli
inadequ
vivo
applic
context
cellpenetr
peptid
see
repres
interest
altern
gener
less
toxic
liposom
cation
polym
moreov
commonli
better
suit
transfer
cargo
differ
cell
type
like
nonadher
cell
primari
cell
hard
transfect
use
commerci
avail
standard
protocol
advanc
approach
field
subject
present
articl
complex
carrier
system
combin
vantag
assort
strategi
gener
nanoparticl
better
defin
properti
aim
toward
enhanc
uptak
well
intracellular
traffick
combin
cellspecif
function
exampl
attempt
combin
peptid
cation
liposom
polyethyleneimin
pei
strategi
aim
toward
synthesi
high
low
molecular
weight
branch
polym
andor
peptid
dendrim
even
complex
system
particularli
promis
respect
vivo
deliveri
review
report
particular
aspect
nonvir
oligonucleotid
deliveri
vitro
pinpoint
current
limit
provid
quantit
mean
determin
bottleneck
strategi
present
focu
articl
recent
progress
field
peptidemedi
cellular
deliveri
sirna
steric
block
oligonucleotid
cell
tissu
cultur
start
point
develop
illustr
experiment
data
intent
provid
reader
easi
solut
solv
exist
problem
encount
approach
give
hint
start
optim
particular
approach
idea
use
peptid
carrier
goe
back
twenti
year
discov
transactiv
protein
tat
taken
mammalian
cell
year
later
antennapedia
homeodomain
drosophila
melanogast
shown
act
similarli
later
could
shown
peptid
deriv
tat
antennapedia
well
protein
capabl
transport
macromolecular
cargo
molecul
cell
base
promis
result
rapidli
expand
field
focus
socal
cellpenetr
peptid
cpp
also
refer
protein
transduct
domain
ptd
began
develop
sinc
first
report
tat
larg
number
natur
occur
well
engin
cpp
discov
tabl
give
overview
select
classic
cpp
gener
cpp
short
polycation
sequenc
less
amino
acid
abl
transloc
differ
cargo
eg
nucleic
acid
peptid
even
entir
protein
cell
common
characterist
peptid
appear
amphipath
net
posit
charg
physiolog
ph
frequent
cargo
coval
attach
cpp
achiev
express
fusion
construct
chemic
coupl
review
see
particular
case
cargo
carrier
bind
noncoval
mainli
ionic
interact
despit
widespread
interest
peptid
carrier
mechan
underli
cellular
transloc
cpp
poorli
understood
earli
work
reli
upon
fluoresc
imag
flow
cytometri
analysi
chemic
fix
cell
examin
intracellular
local
fluoresc
label
peptid
absenc
presenc
cargo
accord
experi
peptid
appear
intern
rapidli
within
minut
even
observ
conclud
cpp
penetr
cell
membran
energyindepend
mechan
although
report
quit
earli
certain
fixat
procedur
may
caus
artefact
lead
overestim
cellular
uptak
rate
dimens
problem
commonli
recogn
side
side
comparison
fix
live
cell
publish
base
find
mani
group
reexamin
data
howev
despit
consider
technic
improv
still
puzzl
controversi
result
concern
exact
mechan
cpp
uptak
though
case
endocytosi
suggest
main
rout
intern
fig
substanti
difficulti
encount
identifi
exact
pathway
refer
therein
prior
endocytosi
cpp
interact
electrostat
extracellular
matrix
cell
surfac
mostli
bind
neg
charg
glycosaminoglycan
ie
heparan
sulfat
proteoglycan
recent
studi
indic
uptak
mechan
cpp
influenc
attach
cargo
exampl
richard
et
al
report
coloc
tat
marker
clathrinmedi
endocytosi
wherea
fittipaldi
et
al
found
caveolaelipid
raftdepend
process
tatgfp
fusion
protein
wadia
et
al
describ
macropinocytot
uptak
pathway
fusion
construct
tat
peptid
cre
recombinas
summari
precis
mechan
intern
remain
elus
strongli
depend
properti
cpp
cargo
well
transfect
condit
cell
line
use
oppos
major
cpp
applic
report
reli
coval
linkag
carrier
cargo
limit
gener
use
consider
new
construct
gener
well
test
given
nucleic
acid
cargo
focu
articl
peptid
term
mpg
form
highli
stabl
noncoval
complex
nucleic
acid
fig
peptid
deriv
origin
mpg
peptid
describ
morri
cowork
differ
five
amino
acid
hydrophob
part
chang
result
alter
overal
structur
peptid
toward
higher
tendenc
adopt
helic
conform
accordingli
two
peptid
behav
penetratin
antp
rqikiwfqnrrmkwkk
transportan
gwtlnsagyllgkinlkalaalakkil
agyllgkinlkalaalakkil
oligoarginin
rrrrrrrr
map
klalklalkalkaalkla
mpg
galflgflgaagstmgawsqpkkkrkv
mpg
galflaflaaalslmglwsqpkkkrkv
differ
respect
interact
artifici
lipid
well
xenopu
oocyt
probabl
exact
mechan
uptak
besid
ionic
interact
respons
initi
peptidenucl
acid
complex
format
hydrophob
peptidepeptid
interact
drive
matur
larg
nanoparticl
sandwichlik
assembl
reaction
fig
fig
recent
year
rna
interfer
rnai
gain
lot
interest
tool
function
genom
studi
probabl
equal
import
promis
therapeut
approach
treatment
variou
diseas
rnai
highli
evolut
conserv
specif
process
posttranscript
gene
silenc
ptg
doubl
strand
rna
dsrna
introduc
cell
caus
sequencespecif
degrad
homolog
mrna
sequenc
mechanist
process
divid
two
step
initi
step
dsrna
cleav
dicer
member
rnase
iii
famili
nt
long
small
interf
rna
sirna
fragment
consecut
step
fragment
transfer
risc
rnainduc
silenc
complex
one
strand
call
guid
strand
serv
molecular
templat
recogn
homolog
mrna
cleav
argonaut
protein
compon
risc
guid
strand
bound
risc
complex
undergo
mani
round
mrna
bind
cleavag
fig
circumv
applic
long
doubl
strand
rna
inevit
trigger
interferon
respons
suffici
extracellularli
suppli
nt
long
dsrna
altern
sirna
express
endogen
use
dna
vector
code
short
hairpin
sh
rna
shrna
cleav
dicer
sirna
short
hairpin
rna
construct
advantag
sirna
effect
construct
lead
stabl
longterm
result
hand
besid
fact
shrna
might
interfer
microrna
pathway
strategi
requir
gene
therapi
approach
long
run
reason
cover
shrna
describ
sirna
repres
valuabl
tool
inhibit
express
target
gene
sequencespecif
manner
follow
section
select
exampl
cppmediat
sirna
deliveri
present
summar
tabl
studi
describ
coval
attach
nucleic
acid
cargo
peptid
carrier
confer
tabl
one
approach
simpl
mix
sirna
target
gfp
tat
peptid
gener
measur
rnai
effect
wherea
crosslink
sirnatat
led
signific
downregul
target
protein
howev
high
concentr
sirna
nm
use
lfand
tat
mediat
transfect
result
perinuclear
local
sirna
contrast
fluoresc
label
tat
without
cargo
mainli
found
nucleolu
suggest
interact
risc
influenc
subcellular
local
anoth
approach
signific
uptak
sirna
target
luciferas
gfp
could
observ
disulfid
coupl
sens
strand
penetratin
transportan
compar
slightli
higher
level
transfect
achiev
interestingli
transfect
basal
luciferas
activ
return
normal
level
one
day
earlier
cppmediat
transfect
although
concentr
sirna
appli
remark
strong
rnai
effect
hard
transfect
primari
neuron
cell
report
davidson
et
al
sirna
direct
sever
endogen
protein
coupl
penetratin
via
disulfid
bond
observ
regul
target
protein
peptidemedi
sirna
deliveri
found
far
effect
compar
part
attribut
toxic
lipid
one
first
group
report
tat
penetratinmedi
sirna
deliveri
vivo
moscho
et
al
show
intratrach
administr
conjug
lead
intensif
knockdown
target
gene
mitogenactiv
protein
kinas
mous
lung
comparison
unmodifi
nonformul
sirna
strikingli
found
peptid
alon
trigger
detect
decreas
target
gene
express
penetratinconjug
induc
elev
level
immun
marker
ifn
tnf
lung
tissu
besid
technic
difficulti
aris
synthes
conjug
consist
short
cation
hydrophob
peptid
highli
neg
charg
sirna
dowdi
group
present
rather
critic
point
view
refer
previou
studi
cppsirnaconjug
claim
success
deliveri
describ
therein
sole
result
excess
free
peptid
lead
addit
complex
therebi
cellular
import
sirna
accord
turner
et
al
first
observ
care
purif
cppantisenseconjug
abrog
biolog
effect
among
thing
might
reason
studi
report
success
peptidemedi
deliveri
sirna
use
noncoval
complex
approach
confer
tabl
simeoni
et
al
first
noncoval
complex
sirna
peptid
mpg
ratio
neg
nucleic
acid
posit
peptid
charg
decreas
luciferas
activ
detect
hela
cell
effect
enhanc
downregul
mutat
nl
sequenc
carrier
peptid
mpg
nl
presum
due
increas
deliveri
cytoplasm
risc
local
recent
veldhoen
et
al
use
deriv
mpg
peptid
deliveri
sirna
describ
chapter
mpg
mediat
deliveri
sirna
steric
block
oligonucleotid
leng
et
al
present
promis
result
prospect
cellspecif
sirna
deliveri
differ
version
branch
histidin
lysinepolym
yield
knockdown
target
gene
sever
cell
type
structurefunct
studi
reveal
import
role
composit
histidinerich
domain
well
posit
within
peptid
branch
sirna
deliveri
wherea
size
surfac
charg
effect
furthermor
toxic
much
lower
commerci
cation
lipid
oligofectamin
final
attach
tripeptid
rgd
integrinligand
slightli
enhanc
sirna
deliveri
turn
carrier
cellspecif
system
fig
simplist
scheme
peptidebas
nucleic
acid
deliveri
system
interact
cpp
cargo
either
achiev
coval
attach
noncoval
complex
mainli
ionic
interact
case
noncoval
complex
format
assembl
cargocarri
complex
occur
lead
format
larg
nanoparticl
confer
fig
case
coval
join
molecul
similar
scenario
less
like
yet
exclud
prior
transloc
process
particl
attach
cell
surfac
ionic
interact
posit
charg
cpp
residu
neg
charg
membran
compon
subsequ
complex
taken
via
endocytot
pathway
although
less
like
direct
penetr
exclud
may
occur
simultan
insid
cell
cargo
escap
vesicular
compart
otherwis
eventu
get
degrad
lysosom
red
neg
charg
blue
posit
charg
green
hydrophob
domain
threedimension
model
mpg
sirna
interact
b
model
gener
iter
rigid
bodi
dock
cycl
sirna
pdb
peptid
use
program
hex
pdb
file
mpg
gener
program
icm
molsoft
llc
take
consider
differ
secondari
structur
predict
energi
minim
protocol
mani
dock
solut
particular
one
pick
illustr
purpos
use
program
chimera
phosphat
backbon
sirna
shown
red
nucleobas
light
gray
aliphat
aromat
hydrophob
residu
peptid
shown
green
posit
charg
residu
blue
remain
amino
acid
gray
assum
format
larger
particl
driven
hydrophob
peptidepeptid
interact
gener
free
posit
charg
sirna
molecul
interact
eventu
drive
complex
format
sandwich
mesh
like
assembl
reaction
principl
scenario
hold
true
given
nucleic
acid
cargo
similar
concept
recent
use
kumar
et
al
specif
deliveri
approach
brain
peptid
deriv
rabi
viru
glycoprotein
rvg
interact
specif
nicotin
acetylcholin
receptor
achr
neuron
cell
enabl
viral
entri
author
could
show
biotinyl
form
peptid
ytiwmpenprpgtpcdiftnsrgkrasng
taken
neuron
cell
order
transport
nucleic
acid
vehicl
r
conjug
rvg
peptid
system
treatment
mice
sirna
noncoval
complex
modifi
peptid
promot
highli
specif
cellular
import
sirna
cell
express
achr
even
import
antivir
sirna
treatment
result
success
protect
mice
enceph
caus
japanes
enceph
viru
jev
first
studi
report
nontox
method
deliv
sirna
across
blood
brain
barrier
could
help
circumv
danger
ineffect
inject
brain
date
present
one
promis
tissuespecif
deliveri
approach
might
expand
vivo
applic
along
line
studi
today
perform
aim
cppmediat
sirna
deliveri
vivo
although
mani
alreadi
show
promis
result
eg
concern
tumortarget
ocular
deliveri
beyond
scope
review
discuss
elsewher
issu
aim
increas
endosom
escap
sirna
peptidemedi
deliveri
lundberg
et
al
ration
modifi
penetratin
form
cpp
term
improv
endosomolyt
properti
achiev
phdepend
conform
chang
peptid
higher
degre
helic
replac
two
basic
amino
acid
histidin
ntermin
addit
six
amino
acid
studi
sever
cpp
compar
noncoval
approach
measur
overal
cellular
nc
egfp
primari
rat
hippocamp
neuron
core
nc
luciferas
hela
uptak
via
fluoresc
biolog
effect
sirna
target
luciferas
mrna
penetratina
well
transfect
lead
silenc
luciferas
gene
express
despit
high
amount
intracellular
sirna
contrast
previou
report
use
sirnapenetratinconjug
deliveri
nm
sirna
led
approxim
reduct
luciferas
activ
silenc
effect
slightli
better
bprpp
rang
mpg
nl
still
pronounc
transfect
nm
sirna
describ
earlier
addit
phsensit
peptid
deriv
hemagglutinin
promot
endosom
escap
author
link
penetratin
turn
although
improv
silenc
effect
coincub
penetratin
potent
combin
peptid
togeth
confoc
microscopi
studi
author
conclud
lack
biolog
effect
penetratinmedi
sirna
deliveri
due
lack
endosom
escap
superior
endosomolyt
activ
comparison
endoh
et
al
recent
present
innov
strategi
call
cliprnai
ie
cpplink
rbpmediat
rna
intern
photoinduc
rnai
combin
deliveri
specif
rna
sequenc
enhanc
photoinduc
releas
rna
endosom
goal
accomplish
fuse
rnabind
domain
rbd
tat
peptid
extend
sirna
short
stretch
nucleotid
specif
recogn
rbd
complex
effici
intern
exhibit
punctuat
cytoplasm
local
pattern
indic
endosom
entrap
howev
photostimul
fluorophor
attach
peptid
led
redistribut
complex
cytosol
follow
effici
rnaimedi
gene
silenc
human
premrna
contain
averag
eight
express
sequenc
exon
averag
length
nt
interven
sequenc
intron
vari
length
nt
therefor
compris
transcript
unit
nucleu
ribonucleoprotein
complex
call
spliceosom
recogn
exonintron
boundari
catalyz
precis
remov
intron
subsequ
join
exon
process
call
rna
splice
addit
primari
transcript
yield
differ
matur
rna
altern
splice
therebi
expand
inform
content
versatil
transcriptom
eg
product
protein
isoform
recent
studi
human
gene
reveal
least
multiexon
gene
altern
splice
sever
differ
type
altern
splice
amongst
other
affect
transcript
start
site
splice
site
polyadenyl
site
even
whole
intron
exon
disrupt
intric
splice
pattern
tightli
coupl
human
pathophysiolog
either
determin
direct
caus
diseas
modifi
diseas
suscept
sever
among
diseas
thalassemia
cystic
fibrosi
muscular
dystrophi
frasier
syndrom
certain
kind
dementia
cancer
detail
descript
underli
mechan
beyond
focu
articl
found
number
review
et
al
propos
mutat
caus
diseas
lead
splice
defect
rather
chang
amino
acid
sequenc
two
common
form
mutat
depict
fig
one
hand
mutat
splice
donor
favor
recognit
cryptic
splice
donor
result
mutant
mrna
contain
addit
intron
sequenc
part
hand
mutat
splice
acceptor
lead
skip
whole
exon
result
shorten
mrna
part
ii
scenario
use
context
antisens
oligonucleotidemedi
approach
target
altern
splice
use
antisens
oligonucleotid
interact
mrna
affect
protein
product
goe
back
year
sinc
three
principl
mechan
exploit
purpos
review
see
oligonucleotiderna
duplex
form
substrat
endogen
rnase
h
lead
mrna
cleavag
ii
oligonucleotiderna
duplex
prevent
product
assembl
ribosom
complex
arrest
ribosom
complex
alreadi
engag
translat
case
affect
protein
biosynthesi
iii
oligonucleotiderna
duplex
alter
premrna
splice
nucleu
follow
section
focu
last
approach
aim
treat
splice
disord
give
exampl
possibl
applic
cpp
context
differ
form
human
thalassemia
caus
mutat
within
globin
intron
activ
cryptic
splice
site
thu
lead
format
nonfunct
transcript
fig
part
aberrantli
use
site
block
antisens
steric
block
oligonucleotid
lead
synthesi
function
protein
kole
group
adopt
principl
develop
splice
correct
assay
model
system
firefli
luciferas
construct
lead
synthesi
inact
enzym
report
gene
premrna
interrupt
human
globin
intron
contain
aberr
splice
site
upon
bind
steric
block
oligonucleotid
correct
splice
restor
turn
yield
function
luciferas
protein
achiev
oligonucleotid
deliv
nucleu
furthermor
oligonucleotid
nt
activ
rnase
h
applic
eg
phosphorodiamid
morpholino
oligom
pmo
lock
nucleic
acid
lna
peptid
nucleic
acid
pna
oligonucleotid
ome
addit
inabl
activ
rnase
h
modif
confer
higher
affin
target
rna
increas
resist
enzymat
degrad
unmodifi
version
compar
rnaibas
model
system
assay
less
suscept
side
effect
like
cytotox
offtarget
effect
report
gene
activ
turn
rather
turn
splice
correct
assay
success
appli
analysi
sever
carrier
system
follow
section
select
exampl
present
summar
tabl
contrast
mani
noncoval
cppmediat
sirna
deliveri
approach
effici
splice
correct
achiev
conjug
peptid
steric
block
oligonucleotid
astriabfish
et
al
describ
deliveri
ome
rna
phosphorothio
oligonucleotid
link
via
disulfid
bridg
tat
peptid
penetratin
hour
transfect
cppoligonucleotid
conjug
detect
cytoplasm
vesicl
nucleu
caus
dosedepend
increas
luciferas
activ
find
contrast
result
turner
et
al
could
find
biolog
effect
sever
cppoligonucleotid
conjug
hela
cell
assay
tatmedi
transactiv
long
termin
repeat
author
observ
vesicular
uptak
nuclear
import
highli
pure
conjug
interestingli
rate
uptak
could
enhanc
addit
free
cpp
conjug
though
still
biolog
activ
detect
base
find
turner
et
al
conclud
free
cpp
form
complex
cppcargo
conjug
play
signific
role
uptak
process
accord
observ
mead
et
al
uptak
cppsirna
conjug
describ
moulton
et
al
achiev
correct
missplic
low
micromolar
concentr
r
f
pmo
conjug
complex
peptid
pmo
steric
block
activ
r
f
pmo
conjug
could
increas
longer
spacer
wherea
variat
conjug
chemistri
result
differ
furthermor
transfect
rate
higher
conjug
tat
peptid
penetratin
tat
peptid
analogu
use
transactiv
assay
mention
turner
et
al
could
show
cppoligonucleotid
conjug
attain
biolog
activ
coadministr
endosomolyt
substanc
chloroquin
fluoresc
microscopi
analys
reveal
treatment
releas
fluoresc
label
conjug
endosom
compart
nucleu
besid
addit
chloroquin
differ
endosom
disrupt
strategi
evalu
use
splice
correct
assay
exampl
cotreat
endosomedisrupt
peptid
photochem
intern
see
chapter
strategi
enhanc
endosom
escap
howev
promis
result
achiev
two
newli
develop
deriv
classic
cpp
review
modif
oligoarginin
nonnatur
uncharg
amino
acid
led
amongst
other
peptid
rahxr
ahx
repres
sixatom
aminohexano
acid
spacer
abe
et
al
demonstr
contrast
tat
oligoargin
pmoconjug
peptid
led
dosedepend
splice
correct
low
micromolar
concentr
absenc
endosomolyt
agent
underli
mechan
superior
activ
clear
yet
uptak
rahxr
construct
less
effici
uptak
tat
oligoarginin
construct
also
involv
endocytot
rout
second
peptid
deriv
penetratin
six
arginin
residu
ad
nterminu
r
pen
r
penpna
conjug
shown
promot
effici
splice
correct
low
concentr
absenc
endosomolyt
agent
uptak
r
penconjug
seem
involv
endocytosi
hardli
differ
splice
correct
activ
regardless
natur
linker
use
conjug
eg
stabl
thioether
versu
reduc
disulfid
linker
part
ii
fig
illustr
phenomenon
repres
strategi
treatment
duchenn
muscular
dystrophi
dmd
dmd
sever
progress
neuromuscular
disord
caus
sever
differ
mutat
dystrophin
gene
abolish
product
function
protein
depend
locat
mutat
correspond
exon
skip
cover
respons
splice
site
steric
block
oligonucleotid
allow
transcript
intern
delet
larg
function
dystrophin
protein
convert
sever
dmd
milder
becker
muscular
dystrophi
phenotyp
detail
descript
approach
applic
number
anim
model
found
sever
excel
recent
review
success
system
deliveri
splice
switch
oligonucleotid
without
chemic
modif
pmo
lna
ome
accomplish
via
inject
nake
nucleic
acid
help
viral
vector
reimplant
ex
vivo
manipul
stem
cell
combin
cpp
latter
purpos
sever
studi
carri
novel
deriv
argininerich
peptid
contain
differ
number
nonamino
acid
eg
aminohexano
acid
andor
alanin
cpppmo
conjug
show
higher
serum
stabil
less
endosom
trap
led
effici
exon
skip
myoblast
mice
lower
dosag
splice
switch
pmo
alon
yin
et
al
use
pnamodifi
spliceswitch
oligonucleotid
conjug
tat
muscl
specif
peptid
msp
differ
function
domain
adenoviru
capsid
protein
examin
exon
skip
effici
vitro
vivo
surprisingli
transfect
intramuscular
inject
activ
pnapeptid
conjug
significantli
better
achiev
nake
neutral
pna
presum
due
endosom
trap
intracellular
traffick
repres
one
major
limit
current
nonvir
nucleic
acid
deliveri
approach
word
larg
percentag
intracellular
cargo
molecul
entrap
vesicular
compart
thu
trigger
desir
effect
moreov
degrad
retrograd
transport
might
reduc
number
activ
molecul
order
determin
overal
efficaci
given
deliveri
approach
essenti
know
number
intact
cargo
molecul
insid
cell
along
minim
number
molecul
requir
caus
particular
effect
base
inform
one
easili
calcul
percentag
bioactiv
molecul
follow
chapter
briefli
describ
select
exampl
variabl
suitabl
quantit
determin
nucleic
acid
cellular
context
principl
either
peptid
cargo
label
report
group
eg
radioisotop
fluorophor
fluoresc
peptid
cargo
quantit
evalu
fac
fluoresc
correl
microscopi
fc
fret
case
crucial
distinguish
intern
membraneassoci
signal
purpos
simpl
wash
step
buffer
suffici
complet
remov
membranebound
peptidecargocomplex
extracellularli
bound
complex
effici
remov
exampl
enzymat
digest
trypsin
acid
wash
heparin
treatment
altern
discrimin
intraand
extracellular
materi
possibl
chemic
modif
extracellular
compon
fluoresc
quench
establish
intracellular
signal
taken
account
still
challeng
distinguish
intact
degrad
form
peptid
cargo
two
studi
fluorescencebas
quantif
method
combin
either
hplc
analysi
cell
activ
capillari
electrophoresi
verifi
integr
cargo
carrier
recent
techniqu
measur
cellular
uptak
cpp
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
report
group
burlina
quantif
base
addit
intern
standard
ie
peptid
stabl
isotop
label
method
use
determin
amount
stabil
intact
intern
peptid
eg
penetratin
sever
novel
cpp
also
use
quantif
peptid
cargo
eg
inhibitor
protein
kinas
c
varga
et
al
develop
integr
system
approach
combin
quantit
experi
comput
model
studi
vector
uptak
traffick
kinet
aim
take
multipl
potenti
ratelimit
cellular
molecular
process
account
appli
mathemat
model
plasmid
deliveri
either
lipofectamin
sever
peibas
vector
formul
adenovir
vector
could
success
predict
experiment
observ
effect
identifi
endosom
escap
import
ratelimit
intracellular
barrier
nonvir
vector
recent
zhou
et
al
appli
similar
strategi
character
novel
lipopolym
wlsp
carrier
show
increas
rate
endosom
escap
compar
convent
peibas
carrier
aim
quantifi
rhodaminelabel
plasmid
dna
cellular
compart
avoid
problem
aris
subcellular
fraction
like
recoveri
leakag
akita
et
al
develop
novel
quantit
strategi
confoc
imageassist
threedimension
integr
quantif
cidiq
method
distinguish
endosomeslysosom
nucleu
cytosol
stain
lysosensor
hoechst
respect
sequenti
zseri
imag
captur
clsm
appli
quantif
method
author
could
show
due
rapid
endosom
escap
lipofectamin
plu
deliv
plasmid
nucleu
stearyl
hama
et
al
use
method
combin
taqman
pcr
evalu
uptak
intracellular
distribut
plasmid
dna
deliveri
viral
well
nonvir
vector
due
superior
cell
surfac
bind
effici
cellular
uptak
significantli
higher
lipofectamin
plu
adenoviru
wherea
intracellular
traffick
ie
endosom
escap
nuclear
transfer
essenti
howev
achiev
compar
transgen
express
higher
intranuclear
plasmid
number
requir
case
lipofectamin
plu
find
suggest
differ
nuclear
transcript
effici
nonvir
deliveri
anoth
approach
jiang
et
al
extend
end
sens
strand
sirna
nucleaseresist
dna
hairpin
obtain
socal
crook
sirna
modif
effect
rnaimedi
report
gene
inhibit
serv
primer
fillingin
reaction
follow
pcr
paramet
chosen
initi
rate
templat
amplif
correl
initi
concentr
crook
sirna
condit
quantif
attomolar
sirna
level
per
cell
possibl
liposom
transfect
oligofectamin
highli
sensit
method
develop
overhoff
et
al
detect
sirna
phosphorothioatestimul
uptak
adapt
quantif
sirna
steric
block
oligonucleotid
noncoval
peptidemedi
deliveri
laufer
et
al
manuscript
prepar
see
chapter
mpg
mediat
deliveri
sirna
steric
block
oligonucleotid
socal
liquid
hybrid
assay
base
extract
total
cellular
rna
subsequ
hybrid
solut
radioact
label
probe
complementari
oligonucleotid
detect
final
follow
page
analysi
absolut
amount
intern
oligonucleotid
quantifi
high
accuraci
molecul
per
cell
use
intern
standard
addit
outstand
sensit
amplif
step
need
intact
oligonucleotid
taken
account
consid
multitud
avail
cpp
nucleic
acid
cargo
cellular
well
anim
model
system
comparison
differ
deliveri
strategi
seem
nearli
imposs
context
first
time
undertaken
detail
side
side
comparison
two
differ
model
system
use
peptid
mpg
deliveri
agent
follow
paragraph
present
experiment
data
exemplarili
illustr
particular
aspect
regard
current
limit
peptidebas
deliveri
system
contrast
mani
cpp
procedur
reli
coval
linkag
carrier
cargo
peptid
mpg
form
highli
stabl
noncoval
complex
nucleic
acid
display
bind
constant
low
nanomolar
rang
tramp
unpublish
data
high
flexibl
noncoval
approach
exploit
easili
transport
wide
varieti
nucleic
acid
cargo
without
synthes
new
construct
oligonucleotid
use
mpg
deliveri
sirna
context
rnaibas
report
system
deliveri
steric
block
oligonucleotid
context
splice
correct
assay
describ
mpg
mediat
transfect
luciferasetarget
sirna
observ
strong
inhibit
report
gene
readout
ic
subnanomolar
rang
mpg
mediat
transfect
luciferasetarget
steric
block
oligonucleotid
also
refer
observ
moder
upregul
report
gene
readout
repres
low
splice
correct
activ
laufer
et
al
manuscript
prepar
one
possibl
explan
differ
degre
report
gene
regul
could
differ
intracellular
target
site
ie
cytoplasm
sirna
nucleu
splice
correct
oligonucleotid
attain
inform
subcellular
local
mpg
oligonucleotid
complex
perform
confoc
laser
scan
well
convent
fluoresc
microscopi
studi
fluoresc
label
sirna
steric
block
oligonucleotid
case
punctuat
nonhomogen
distribut
nucleic
acid
insid
cell
observ
pattern
indic
accumul
nucleic
acid
endocytot
vesicl
verifi
coincub
lysosensor
fig
quantit
comput
analysi
fluoresc
microscopi
data
yield
averag
approxim
coloc
endosom
sirna
fig
contrast
earlier
assumpt
cpp
directli
travers
lipid
bilay
commonli
becom
accept
peptidecargo
combin
endocytosi
play
major
role
cellular
uptak
describ
chapter
strategi
enhanc
endosom
escap
administr
endosom
disrupt
substanc
like
chloroquin
greatli
increas
endosom
releas
trap
nucleic
acid
chloroquin
weak
base
noncharg
neutral
ph
charg
ph
abl
pass
easili
membran
uncharg
form
becom
proton
accumul
within
acid
vesicl
posit
charg
membraneimperm
form
although
exact
mode
action
yet
resolv
gener
accept
chloroquin
work
via
prevent
endosom
acidif
turn
increas
resid
time
cargo
within
endosom
eventu
result
higher
probabl
transfer
cytoplasm
fluoresc
microscopi
analys
presenc
chloroquin
yield
two
quit
contrari
outcom
local
sirna
chang
addit
chloroquin
fig
steric
block
oligonucleotid
pictur
chang
complet
fig
latter
case
diffus
fluoresc
cytoplasm
accumul
nucleu
could
observ
nonetheless
consider
amount
nucleic
acid
molecul
still
visibl
punctual
pattern
indic
chloroquin
treatment
liber
certain
fraction
whole
qualit
observ
full
agreement
observ
biolog
effect
absenc
presenc
chloroquin
fig
mpg
mediat
transfect
sirna
even
condit
amount
bioavail
sirna
sever
limit
minor
increas
rnai
ca
measur
mpg
mediat
transfect
steric
block
oligonucleotid
hand
dramat
increas
report
gene
upregul
factor
observ
howev
case
overal
uptak
chang
upon
incub
chloroquin
fig
prove
endosomolyt
substanc
interfer
uptak
lead
redistribut
intern
nucleic
acid
underli
mechan
differ
effect
trigger
chloroquin
case
peptidesirna
peptidester
block
oligonucleotid
complex
remain
unclear
though
good
exampl
cargo
substanti
affect
properti
therebi
intracellular
traffick
particular
carrier
system
ultim
assess
overal
efficaci
carrier
system
interest
elucid
percentag
molecul
taken
mpg
mediat
deliveri
biolog
activ
deriv
inform
exact
intracellular
amount
intact
oligonucleotid
correspond
report
signal
minim
number
molecul
necessari
trigger
specif
degre
report
gene
modul
known
quantif
intern
cargo
adapt
highli
sensit
method
first
describ
overhoff
et
al
enabl
us
detect
intracellular
oligonucleotid
amount
copi
per
cell
method
base
liquid
hybrid
radioact
label
probe
correspond
oligonucleotid
cellular
lysat
context
note
stringent
heparin
wash
follow
transfect
procedur
crucial
avoid
overestim
intracellular
nucleic
acid
molecul
due
complex
attach
outsid
cell
membran
order
correl
number
deriv
quantif
experi
minim
number
molecul
essenti
trigger
observ
effect
independ
assay
establish
gold
standard
case
microinject
techniqu
enabl
one
deliv
definit
amount
nucleic
acid
high
degre
bioavail
cytoplasm
nucleu
mammalian
cell
along
low
toxic
profil
great
accuraci
consid
cytoplasm
microinject
sirna
molecul
suffici
halfmaxim
inhibit
report
gene
express
one
estim
molecul
measur
mpgmediat
transfect
ca
biolog
activ
tabl
splice
correct
assay
number
differ
term
absolut
number
outcom
remain
compar
molecul
suffici
maxim
splice
correct
nuclear
microinject
molecul
requir
follow
peptidemedi
deliveri
ca
biolog
activ
tabl
case
intern
oligonucleotid
like
retain
endosom
subsequ
degrad
lysosom
peptidemedi
deliveri
frankli
sober
result
put
number
much
room
improv
actual
though
certainli
legitim
gener
find
countless
report
literatur
suggest
similar
limit
major
nonvir
strategi
accord
actual
concept
sirna
enter
multipleturnov
pathway
one
sirna
molecul
capabl
riscmedi
cleavag
mrna
molecul
even
though
fate
steric
block
oligonucleotid
realli
clear
assum
per
splice
event
one
molecul
use
translat
function
mrna
molecul
eg
singleturnov
pathway
result
number
molecul
need
trigger
appar
effect
much
higher
splice
correct
assay
compar
rnaibas
report
system
confer
tabl
tabl
hand
singleturnov
pathway
splice
correct
assay
much
sensit
even
minor
chang
intracellular
steric
block
oligonucleotid
concentr
wherea
catalyt
natur
multipleturnov
rnai
mechan
might
mask
small
variat
accord
data
describ
taken
togeth
base
result
present
well
unpublish
data
laufer
et
al
manuscript
prepar
splice
correct
assay
appear
superior
tool
quantit
assess
nucleic
acid
deliveri
strategi
outlin
endosom
releas
one
major
ratelimit
step
cellular
deliveri
macromolecul
via
cation
lipid
polyplex
especi
cpp
follow
chapter
present
exampl
increas
endosom
releas
transfect
perform
mpg
nm
sirna
gml
nm
sirna
ie
rang
valu
quantif
perform
h
accord
liquid
hybrid
protocol
molecul
per
cell
calcul
base
cell
number
seed
transfect
microinject
experi
molecul
per
cell
calcul
basi
inject
volum
endosomedisrupt
substanc
like
chloroquin
calcium
sucros
use
significantli
enhanc
activ
antisens
pna
oligonucleotid
conjug
tat
oligoarginin
oligolysin
effect
result
increas
uptak
rather
improv
bioavail
cytoplasm
nucleu
endosom
escap
takeuchi
et
al
show
incub
target
cell
pyrenebutyr
deliveri
argininerich
peptid
could
shift
endocyt
uptak
direct
membran
transloc
yield
rapid
distribut
peptid
throughout
cytoplasm
even
pyrenebutyr
act
counteranion
interact
posit
charg
peptid
increas
overal
hydrophob
therebi
facilit
direct
transloc
lipid
bilay
earlier
shown
artifici
membran
method
work
absenc
medium
serum
success
appli
administr
fluoresc
protein
apoptosisinduc
peptid
divid
well
nondivid
cell
howev
gener
strategi
describ
feasibl
vivo
applic
due
high
cytotox
undesir
secondari
effect
imidazol
group
histidin
absorb
proton
acid
environ
endosom
lead
osmot
swell
membran
disrupt
eventu
nucleic
acid
escap
accordingli
lo
et
al
modifi
tat
bind
condens
dna
ionic
interact
acid
residu
promot
endosom
releas
differ
number
residu
highest
report
gene
express
could
achiev
plasmid
deliveri
tat
peptid
coval
fuse
residu
insert
two
addit
cystein
residu
enhanc
stabil
peptidedna
complex
transgen
express
format
interpeptid
disulfid
bond
youngblood
et
al
evalu
influenc
stabil
argininerich
peptid
pmo
conjug
cellular
uptak
antisens
activ
could
show
stabil
affect
amino
acid
composit
type
linkag
cargo
moreov
found
degrad
fragment
could
escap
anymor
endosom
lysosom
compart
anoth
concept
make
use
photosensit
substanc
induc
releas
macromolecul
vesicl
light
exposur
socal
photochem
intern
pci
past
use
intracellular
deliveri
larg
varieti
macromolecul
review
recent
endosom
releas
nucleic
acid
deliveri
mediat
liposom
polyplex
cpp
shiraishi
et
al
investig
biolog
activ
pna
conjug
either
tat
klapeptid
combin
pci
treatment
depend
peptid
nuclear
well
cytosol
antisens
effect
could
enhanc
two
order
magnitud
similar
result
present
folini
et
al
pna
target
human
telomeras
revers
transcriptas
conjug
tat
studi
lower
nucleic
acid
dose
suffici
therebi
reduc
probabl
offtarget
effect
light
encourag
data
ongo
anticanc
clinic
trial
employ
photodynam
therapi
vivo
applic
pci
seem
feasibl
discuss
detail
oliveira
et
al
issu
furthermor
target
specif
could
increas
local
illumin
cell
tissu
viral
fusion
protein
drive
fusion
process
viral
membran
endosom
host
cell
membran
phdepend
manner
requir
transloc
viral
genom
cytoplasm
receptormedi
endocytosi
fusogen
peptid
usual
hydrophob
rich
glycin
residu
found
amino
terminu
protein
shown
membran
perturb
lipid
mix
activ
mani
well
studi
repres
group
deriv
fusion
sequenc
influenza
viru
ha
use
improv
transfect
effici
nonvir
deliveri
system
addit
influenzaderiv
dimer
peptid
complex
effect
particl
size
ca
nm
significantli
improv
gene
silenc
activ
sirna
target
epiderm
growth
factor
receptor
kra
oncogen
similar
result
obtain
plasmid
deliveri
addit
fusogen
peptid
deriv
herp
simplex
viru
glycoprotein
h
lipofectaminedna
complex
end
futaki
et
al
use
peptid
gala
special
design
mimic
function
viral
fusion
sequenc
togeth
variou
commerci
avail
cation
liposom
although
could
detect
signific
differ
cellular
local
plasmid
transfect
effici
increas
liposom
dosag
could
reduc
pei
coval
modifi
peptid
hgp
led
increas
gene
express
plasmid
dna
deliveri
also
enhanc
sirnamedi
knockdown
gapdh
approxim
cell
incub
peihgp
polyplex
show
punctuat
plasmid
dna
stain
observ
pei
polyplex
alon
also
diffus
fluoresc
throughout
cell
indic
endosom
releas
vector
would
explain
observ
increas
transfect
effici
sinc
overal
uptak
unaffect
wadia
et
al
first
use
influenza
hemagglutininderiv
fusogen
peptid
combin
cpp
deliveri
conjug
increas
concentr
tatcr
conjug
enhanc
report
protein
activ
presum
increas
releas
macropinosom
fusogen
peptid
link
conjug
promot
releas
macropinosom
subsequ
transloc
nucleu
accompani
enhanc
anticanc
effect
develop
deliveri
system
therapeut
oligonucleotid
fast
grow
field
owe
enorm
potenti
short
nucleic
acid
altern
drug
growth
unexpect
besid
viral
vector
highli
divers
constantli
increas
number
nonvir
system
evolv
howev
despit
consider
progress
achiev
recent
year
even
advanc
system
either
lack
effici
requir
downstream
drug
develop
show
substanti
degre
toxic
mani
factor
limit
use
cellular
uptak
cargocarri
complex
subsequ
intracellular
traffick
reach
target
site
import
addit
essenti
consider
variou
addit
paramet
taken
account
like
serum
stabil
pharmacokinet
featur
tissu
barrier
well
target
cell
specif
question
aris
start
optim
given
deliveri
system
current
clear
trend
toward
vivo
test
principl
develop
step
right
direct
sinc
mani
experiment
data
deriv
artifici
cell
tissu
cultur
system
establish
cell
line
applic
vivo
situat
hand
question
extent
anim
experi
eventu
pay
long
import
fundament
problem
remain
larg
unsolv
outlin
quantit
studi
along
microscop
analys
sirna
steric
block
oligonucleotid
use
either
peptid
commerci
avail
cation
lipid
carrier
clearli
show
less
molecul
taken
involv
biolog
respons
ie
rnaimedi
regul
splice
correctionmedi
regul
report
gene
activ
evid
vast
major
intern
cargo
never
reach
target
impli
uptak
per
se
limit
factor
although
detail
quantit
number
avail
literatur
system
countless
report
show
variou
degre
appli
almost
nonvir
deliveri
approach
current
avail
taken
togeth
one
would
succeed
optim
intracellular
traffick
hold
potenti
boost
overal
efficaci
order
magnitud
moreov
reason
assum
fundament
cellular
restrict
adequ
investig
tissu
cultur
without
use
anim
model
might
worthwhil
reconsid
concept
mayb
prematur
vivo
test
move
backward
one
step
first
optim
system
regard
intracellular
limit
deal
next
level
complex
accordingli
vitro
model
system
like
one
describ
sirna
steric
block
oligonucleotid
valuabl
tool
studi
particular
aspect
nucleic
acid
deliveri
howev
current
avail
data
base
studi
use
varieti
differ
cell
line
techniqu
render
direct
comparison
differ
deliveri
approach
imposs
context
would
highli
desir
introduc
standard
protocol
vitro
test
eg
splice
correct
system
develop
kole
cowork
togeth
method
detail
quantit
analys
eg
liquid
hybrid
protocol
would
facilit
direct
quantit
comparison
exceedingli
divers
approach
least
cellular
level
one
reason
problem
intracellular
traffick
oligonucleotid
aris
mode
carriercargo
complex
taken
cell
today
well
establish
major
complex
taken
via
endosom
pathway
therefor
end
vesicular
compart
escap
order
reach
target
although
mani
attempt
report
trigger
endosom
escap
variou
strategi
either
prove
toxic
achiev
sustain
success
addit
might
reason
encount
difficulti
overcom
intracellular
barrier
unreason
specul
evolut
cell
might
evolv
mechan
avoid
larg
amount
foreign
nucleic
acid
freeli
float
cytoplasm
thu
safe
contain
vesicular
compart
eventu
degrad
altern
might
export
retrograd
transport
coevolut
virus
evid
develop
strategi
circumv
defens
mechan
might
somewhat
naiv
expect
rather
simpl
manmad
carrier
system
capabl
effici
overcom
intrins
barrier
current
develop
toward
complex
elabor
carrier
system
take
account
consider
case
appear
simpl
solut
problem
conclus
despit
signific
progress
field
nucleic
acid
deliveri
vitro
well
vivo
still
long
way
go
becom
standard
procedur
clinic
certain
problem
like
endosom
escap
known
twenti
year
still
far
resolv
order
develop
new
strategi
inform
intracellular
process
involv
nucleic
acid
traffick
need
moreov
would
desir
field
would
move
qualit
descript
toward
quantit
evalu
preferenti
use
standard
model
system
would
allow
comparison
differ
approach
one
anoth
anim
studi
inevit
long
run
still
lot
room
improv
cellular
level
might
worthwhil
fathom
far
push
differ
system
level
